Request Deal Involvement

Amphastar Pharmaceuticals completed the acquisition of BAQSIMI from Eli Lilly for $1.1bn.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Wilson Sonsini Goodrich & Rosati

legal advisors

Wilson Sonsini Goodrich & Rosati

Jefferies & Company

financial advisors

Jefferies & Company

Wells Fargo Securities

debt providers

Wells Fargo Securities

Capital One Financial Corporation

debt providers

Capital One Financial Corporation

JP Morgan

debt providers

JP Morgan

Fifth Third Bancorp

debt providers

Fifth Third Bancorp

East West Bank

debt providers

East West Bank

Cathay Bank

debt providers

Cathay Bank

CIBC World Markets

debt providers

CIBC World Markets

Kirkland & Ellis

legal advisors

Kirkland & Ellis

Covington & Burling

legal advisors

Covington & Burling

JP Morgan

financial advisors

JP Morgan

or

Principals

BAQSIMI

target

BAQSIMI

AMPHASTAR PHARMACEUTICALS

bidder

AMPHASTAR PHARMACEUTICALS

ELI LILLY AND COMPANY

vendor

ELI LILLY AND COMPANY

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Amphastar Pharmaceuticals completed the acquisition of BAQSIMI from Eli Lilly for $1.1bn.